Visudyne

Selected form

Verteporfin

Method of action: Ophthalmologicals, Photosensitizing

Treatment option: Myopia, Histoplasmosis, Macular Degeneration

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Visudyne

Property	Description
Active ingredient	Verteporfin
Form	Lyophilized powder for solution for infusion
Pharmacological class	Photosensitizing agent, Porphin derivative
General purpose	Specialized ophthalmic treatment via light activation
Origin	Synthetic (Benzoporphyrin derivative)

1. The Composition and Classification of Visudyne

Visudyne is a prescription-only medication whose active component is Verteporfin, a synthetic compound classified as a photosensitizing agent. The finished drug product is supplied as a lyophilized powder for solution for infusion, which must be reconstituted before being delivered through intravenous infusion. This specific preparation method is clinically recognized for ensuring the uniform systemic distribution required for its subsequent activation. Verteporfin is chemically identified as a Benzoporphyrin Derivative Monoacid Ring A (BPD-MA), which places it within the unique porphin derivative group. Its status as a specialized, single-ingredient agent manufactured for systemic delivery distinguishes it within the field of ophthalmic therapeutics.

2. Visudyne as a Photodynamic Therapy (PDT) Agent

The primary role of Visudyne is defined by its function as a photodynamic therapy (PDT) agent, a specialized approach to ophthalmic treatment. As a photosensitizing agent, Verteporfin is specifically designed to be a light-activated compound. After systemic administration, the compound requires subsequent exposure to a non-thermal red light to become functional. This precise two-step process—drug delivery followed by light activation—initiates a highly localized photochemical reaction. Verteporfin is a crucial agent in this localized light-activation process, facilitating targeted drug delivery for ocular conditions. This mechanism is useful because it allows therapeutic effects to be tightly confined to the illuminated target tissues, supporting focused intervention within the eye.

Regulatory References

Verteporfin - Drugs and Lactation Database (LactMed) - NCBI Bookshelf

What side effects are possible with Visudyne?

Possible Side Effects and Safety Information

The safety profile of Visudyne (Verteporfin) is classified according to regulatory standards based on the frequency and type of documented adverse reactions. The most notable safety consideration is the drug’s characteristic as a photosensitizing agent, which imposes a specific, time-bound constraint following treatment.

Frequency-Classified Adverse Reactions

The most commonly documented effects in official labeling are classified across several body systems:

Very Common (may affect more than 1 in 10 people): Reactions at the site of intravenous infusion, which may include swelling, pain, or inflammation. Effects on the eye, such as blurred vision, flash blindness, and decreased visual acuity, are also very common.
Common (may affect up to 1 in 10 people): Systemic effects such as headache, weakness (asthenia), and generalized skin reactions related to photosensitivity.
Uncommon and Rare: Less frequent reactions include gastrointestinal effects like nausea and vomiting, changes in blood pressure, and specific eye disorders. Severe systemic allergic reactions, such as anaphylaxis, are rare but documented serious adverse reactions.

Time-Related Safety Constraints

Due to the nature of the active ingredient, patients must avoid direct, unprotected exposure to bright light or sunlight for five days following the infusion. If the drug leaks from the vein (extravasation) during administration, the affected area must be thoroughly shielded from light to prevent the development of a severe localized burn.

Population-Specific Safety Notes

Official labeling contraindicates the use of Visudyne in individuals with porphyria (a condition that increases light sensitivity) and in cases of known hypersensitivity. Use is also restricted for individuals with severe hepatic impairment, as the compound is primarily processed by the liver. Safety information for pediatric patients has not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory prescribing information for Visudyne (verteporfin) explicitly details the potential manifestations and mandated emergency actions in the event of an overdose, which may be caused by an excessive amount of the drug, the activating laser light, or a combination of both.

Documented Manifestations and Severe Outcomes

An overdose carries the documented risk of acute ocular-vascular complications. The most severe manifestation listed is non-selective non-perfusion of normal retinal vessels in the treated eye, which could lead to a severe decrease in vision. Furthermore, a drug overdose alone may result in the prolongation of the period during which the patient remains photosensitive due to the agent’s systemic presence.

Immediate Actions Required by Regulatory Labeling

Regulatory documentation strictly requires patients to seek emergency medical attention immediately if any overdose is suspected or confirmed. Additionally, patients are instructed to consult with the healthcare practitioner administering the product immediately following the procedure, even in the absence of initial symptoms. Urgent help-seeking is also required for severe acute events such as collapse or seizure, as per standard regulatory guidance.

Supportive Management

There is no specific antidote documented in the official prescribing information. The mandated procedural management is focused on mitigating the risk of light exposure. Patients must prolong skin and eye protection from direct sunlight and bright indoor light for a period proportionate with the documented overdose given.

Therapeutic Uses of Visudyne

Main Uses and Applications

Visudyne is primarily utilized in the management of specific conditions affecting the retina, the light-sensitive layer at the back of the eye. It is most commonly indicated for the treatment of certain forms of age-related macular degeneration (AMD) and other retinal disorders characterized by abnormal blood vessel growth.

Subfoveal Choroidal Neovascularization

The principal application of Visudyne is for patients with subfoveal choroidal neovascularization (CNV). This condition involves the development of abnormal, fragile blood vessels beneath the macula, the central part of the retina responsible for sharp, detailed vision.

In many cases, these vessels are associated with the "wet" form of age-related macular degeneration. Visudyne specifically targets "predominantly classic" CNV lesions, where the boundaries of the abnormal vessel growth are clearly defined during diagnostic imaging.

Other Retinal Conditions

Beyond AMD, Visudyne is also used to treat similar vascular complications resulting from other underlying causes, including:

Pathologic Myopia: Severe nearsightedness can lead to the thinning of retinal tissues and the subsequent growth of abnormal blood vessels beneath the macula.
Ocular Histoplasmosis: A fungal infection that can lead to scarring and the development of CNV in the retina.

Potential Benefits and Goals of Treatment

The primary objective of treatment with Visudyne is the preservation of existing vision by managing the progression of vascular damage.

Stabilization of Vision

The treatment aims to slow or stop the leakage and growth of abnormal blood vessels. By targeting these vessels, the therapy seeks to prevent further damage to the photoreceptor cells in the macula. While it does not typically restore vision already lost to scarring, it is intended to reduce the risk of further moderate to severe vision loss.

Selectivity of Action

Visudyne is designed to work in conjunction with a specific wavelength of non-thermal laser light. This process allows for a targeted approach, where the medication is activated primarily within the abnormal vessels. This selectivity helps limit damage to the surrounding healthy retinal tissue, which is essential for maintaining the integrity of the patient's remaining field of vision.

Eligibility and Restrictions for Use

Visudyne (verteporfin) is indicated for adult patients with the wet form of age-related macular degeneration (AMD), pathologic myopia, or presumed ocular histoplasmosis who have predominantly classic subfoveal choroidal neovascularization (CNV).

Contraindications and Special Considerations

Treatment with Visudyne is not suitable for everyone. It is contraindicated (should not be used) in patients with the following conditions:

Porphyria: A group of rare genetic disorders that affect the nervous system or skin and are characterized by a dangerous buildup of porphyrins.
Known Hypersensitivity: A confirmed allergy or known severe reaction to verteporfin or any other component of the Visudyne preparation.
Severe Hepatic Impairment: Visudyne is excreted primarily through the bile (hepatic route), and severe liver dysfunction may lead to increased drug exposure and risk of toxicity.

Physicians must also use caution in patients with moderate hepatic impairment or biliary obstruction. The safety and effectiveness of Visudyne have not been established in children or adolescents and it is generally not recommended for use in this population. For pregnant or breastfeeding women, the medication should only be used if the potential benefit justifies the potential risk, and it is recommended to avoid breastfeeding for 48 hours after administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Visudyne (verteporfin for injection) has documented interactions with other medicines and substances, primarily due to the potential to enhance its photosensitizing effects or interfere with its mechanism of action. Official regulatory documents identify specific categories of products that require careful consideration or avoidance during treatment.

Key Interaction Domains

Interaction Domain	Practical Implication
Systemic Photosensitizing Agents	Coadministration may significantly increase the risk of severe photosensitivity reactions and should be avoided.
Agents Affecting Drug Uptake	Concomitant use may interfere with the uptake of Visudyne by target cells, potentially reducing treatment effectiveness.
Free Radical Scavengers/Triplet Quenchers	Use may inhibit the necessary photochemical reaction required for treatment, potentially negating the therapeutic effect.

Official Regulatory Statements

Photosensitizing Agents

Patients should avoid concurrent use of other systemic photosensitizing agents, which include certain antibiotics (such as tetracyclines and sulfonamides), some psychiatric medications (phenothiazines), certain diabetes medicines (sulfonylurea hypoglycemic agents), and some diuretics. This constraint also applies to products containing St. John's wort.

Interfering Agents

Medicines that may interfere with the drug’s effectiveness include calcium channel blockers and polymyxin B. Substances that act as free radical scavengers or triplet quenchers, such as dimethyl sulfoxide or preparations containing beta-carotene or lutein, should be considered carefully, as they may inhibit the desired therapeutic effect.

Mechanism of Action

How Visudyne Works

Verteporfin's mechanism is a highly localized photodynamic process, requiring two mechanistic steps. It functions as an inert photosensitizer that preferentially accumulates in the endothelium (inner lining) of abnormal, rapidly growing blood vessels. Once activated by a non-thermal laser light (sim 689 nm), the molecule transitions to an excited state, which facilitates spatial and temporal control over the resulting physiological effects.

Targeted Accumulation and Singlet Oxygen Generation

Following photoactivation, Verteporfin transfers energy to molecular oxygen ( O2), generating highly reactive singlet oxygen (^1 O2) . This short-lived, cytotoxic agent initiates an acute oxidative stress cascade, causing rapid damage specifically to the membranes of the targeted endothelial cells.

Localized Thrombosis and Vascular Occlusion

The acute injury to the endothelial lining activates the local coagulation cascade by exposing pro-coagulant surfaces and releasing vasoactive mediators. This biochemical cascade swiftly triggers platelet aggregation and fibrin clot formation strictly within the lumen of the abnormal vessels. The physiological consequence of this process is the rapid thrombotic occlusion of the targeted neovasculature.

Dosage and Administration Information

Visudyne is administered solely via intravenous infusion (IV) as part of a highly controlled, two-step photodynamic therapy process. The treatment is not a daily regimen but is structured as an intermittent and cyclic procedure, with clinical re-evaluation recommended approximately every 3 months and repeat treatments permitted up to 4 times per year when indicated.

The dose is calculated precisely based on the patient's body surface area (BSA), at a rate of 6 mg/m^2. Before administration, the 15 mg lyophilized powder must be reconstituted, then carefully diluted with 5% Dextrose for Injection to a final volume of 30 mL; normal saline must not be used for this step.

The drug infusion is administered over a mandated 10-minute period, followed by a time-critical activation phase. The non-thermal red laser light delivery must begin precisely 15 minutes after the start of the IV infusion. This administration protocol requires the expertise of ophthalmologists experienced in the procedure.

For certain populations, the standard 6 mg/m^2 dosage is retained for older adults. However, the therapy is contraindicated in severe hepatic impairment. The final solution must be used within 4 hours of preparation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Visudyne

Evidence for Use in Wet Age-related Macular Degeneration (AMD)

The primary evidence for Visudyne (verteporfin) was evaluated in large research efforts, including the TAP Investigation and the VIP Study. These studies monitored adult patients and were designed as randomized controlled trials (RCTs). These research trials examined two key outcomes: visual acuity change and the physical changes in the eye. Visual acuity change was tracked by the proportion of eyes that avoided a significant loss of clarity. The research focused primarily on CNV lesions classified as predominantly classic.

The findings describe patterns where the treated group, particularly those with predominantly classic lesions, differed in the measured proportion of eyes avoiding significant loss compared to the placebo group over the study period. However, the research provided limited information for treating lesions classified as predominantly occult CNV.

Evidence for Use in Pathologic Myopia (PM)

Visudyne was also studied for the treatment of Choroidal Neovascularization (CNV) when it develops secondary to Pathologic Myopia (PM). This research involved a specific, dedicated RCT that utilized a double-masked, placebo-controlled design, focusing on a generally younger adult population. The studies monitored patients over a defined period, with the main goal of exploring short-term symptom changes related to visual acuity. The primary study reported measurements of visual acuity at the one-year mark that differed between the treatment group and the placebo group.

Since the research for PM primarily stems from a single pivotal trial, the sample sizes were modest. The evidence was evaluated for PM-related CNV, but the data for certain groups remain insufficient beyond the direct two-year findings from the main study.

Remaining Research Gaps and Uncertainties

The evidence base contributes to understanding symptom patterns but still contains gaps. The most significant uncertainty lies in the lack of a sufficient evidence base (large, masked RCTs) for CNV lesions that are predominantly occult, limiting the applicability of the findings across the full spectrum of CNV. Additionally, research for CNV associated with Presumed Ocular Histoplasmosis Syndrome (POHS) is limited, relying mainly on smaller, uncontrolled studies.

While long-term effects are not fully established, the extended follow-up data available for AMD and PM provide context but research does not determine whether an individual will respond similarly after five years or more.

Frequently Asked Questions (FAQ)

Common questions about Visudyne (FAQ)

Q: How quickly does Visudyne start working after a procedure?

According to official product information, the treatment's mechanism involves a rapid photochemical reaction. The reaction is initiated immediately by the light activation and leads to the acute occlusion (sealing) of targeted abnormal blood vessels.

Q: Are there any long-term side effects associated with Visudyne treatment?

Studies and official information indicate that the long-term safety and effectiveness of the treatment have not been fully established beyond the two-year monitoring period of the pivotal clinical trials. Extended follow-up data from the original studies provide context for understanding longer-term effects.

Q: Is the procedure for Visudyne painful?

The drug is activated by a non-thermal laser light, meaning the procedure does not involve heat. However, it is common to experience reactions at the intravenous infusion site, which may include localized pain, swelling, or inflammation.

Q: Are there any specific foods or supplements I must avoid while taking Visudyne?

Regulatory documents state that certain supplements, specifically those containing substances that act as free radical scavengers or triplet quenchers (like beta-carotene and lutein), may potentially inhibit the drug's therapeutic effect. Official guidance suggests careful consideration of these substances during treatment.

Q: Does having liver or kidney problems affect eligibility for Visudyne?

Official labeling states that the therapy is contraindicated in severe hepatic impairment (severe liver problems). For individuals with moderate liver impairment or biliary obstruction, the use of the drug must be considered carefully. The effect of kidney impairment has has not been specifically studied.

Q: Is the research evidence for Visudyne considered strong?

The use of Visudyne in treating predominantly classic Choroidal Neovascularization (CNV) secondary to wet Age-related Macular Degeneration (AMD) is supported by data from randomized controlled trials (RCTs). These types of studies are recognized as sources of evidence supporting the use of the drug.

Q: Are there any patient registries or long-term studies following Visudyne use?

While the initial safety and effectiveness trials were not designed to monitor beyond two years, follow-up data from the original clinical studies have been extended. Regulatory information does not specifically mention patient registries, but the extended data helps provide additional context.

Q: Are there specific symptoms that mean I need urgent medical attention after the procedure?

Serious systemic reactions, such as anaphylaxis (a severe allergic reaction), can occur. Sudden, severe decreased vision (a loss of 4 lines or more) within the first week after the procedure has also been reported in clinical experience. Symptoms like difficulty breathing, dizziness, rash, or changes in heart rate are described as reasons to seek immediate medical attention.

Q: Does Visudyne cause a permanent change to the eye tissue?

The drug's mechanism is designed to cause localized damage specifically to the abnormal blood vessels. This injury results in a thrombotic occlusion, which is a targeted seal or blockage of the abnormal neovasculature that prevents further leakage.

Q: Does Visudyne interact with common high blood pressure medications?

Official product information notes interactions with certain types of blood pressure medications. Calcium channel blockers may interfere with the drug's effectiveness, and certain diuretics are listed as systemic photosensitizing agents that can increase the risk of severe light-related skin reactions.

Q: Can I use sunscreen to protect myself after the procedure?

Regulatory warnings indicate that UV sunscreens are not effective in protecting against the photosensitivity reactions caused by the medication. Official guidance states that patients should rely instead on protective measures such as dark sunglasses and covering all exposed skin with clothing for the five-day period following the infusion.

How should Visudyne be stored and disposed of?

Storage and Disposal Requirements for Visudyne

The unopened Visudyne (verteporfin) lyophilized powder must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The vial must be kept in the original outer carton until use for protection from light.

Stability and Handling

Once reconstituted, the solution must be protected from light and used within 4 hours; it is for single use only. Storage must always be out of the sight and reach of children.